2nd Annual Oncology Asia Brochure

LifeSciences

IBCLIFE SCIENCES

Produced by:

International MarketingPartner:

SupportingOrganisation:

ASIA2ND ANNUAL

7 - 9 September 2015 | Sheraton Miyako, Tokyo, Japan

Asia’s Only Event Focusing On Oncology Drug Discovery, ClinicalDevelopment, Commercialization and Cutting-Edge New Advances in

Immuno-Oncology!Featuring Insights From:

Why You ShouldAttend:

TWO separate parallel tracks focusing on:A) Drug DiscoveryB) Clinical & Late Phase-Commercialization

30+ senior industry experts from globaland regional pharmaceuticalcompanies/biotech

Strategically located in Japan, Asia’s leadingR&D destination

Real-life global case studies on oncologycommercialization and drug developmentin Asia

Meet with international and domesticpharma, and leading oncology researchinstitutes

Ming JiSenior Medical Director, Medical Safety Evaluation,AbbVie Global Research & Development, USA

Yoshiya OdaPresident, Biomarkers &Personalized Medicine Unit,Eisai Inc, USA

Dr. M. C. FungVice-President, Oncology Scientific Innovation,Johnson & Johnson Asia-PacificInnovation Center, China

Simon CollierDirector General, European Federation ofPharmaceutical Industries and Associations Japan,Head of Governmental Affairs,Bayer Yakuhin Ltd., Japan

Martina SerschSenior Medical Director, Asia PacificBio-therapeutics Lead, Global DevelopmentClinical Lead, Oncology Therapeutic Area,Roche Pharmaceuticals, USA

Michael LyonsInnovation & Capability Leader,Oncology Business Unit,Eli Lilly KK, Japan

Jean-Francois BaladiSenior Executive, Health Economics andMarket Access, Oncology Business Unit,Novartis Pharma K.K., Japan

Liang SchweizerHead of Asian Cancer Research, Asia-Pacific Research,Sanofi R&D, China

Creative Strategies for Better PatientAdherence to Oncology Drugs in Asia

POST-CONFERENCE WORKSHOPS 9 SEPTEMBER 2015

Workshop A: 9:00 am - 12:30 pm Workshop B: 1:30 pm - 4:30 pm

Gaining FDA Regulatory Approvals for Accelerated DrugDevelopment and Priority Review in Immuno-Oncology

Media Partners:

www.oncologyasia.com

Session SpolightSponsor:

Designing a Pathway for Multinational Clinical Trials in Asia• Identifying the key regulatory requirements for individual Asian countries

for clinical development• Building a clinical development strategy for global trials that incorporates

the clinical trial requirements of each countries• Where does each country fit in the clinical development pathway in Asia?• Identifying the key areas of delay in drug approval, drug-lag and backlog of

approvals for clinical developmentMing Ji, Senior Medical Director, Medical Safety Evaluation, AbbVie GlobalResearch & Development, USAMartina Sersch, Senior Medical Director, Asia Pacific, Bio-therapeutics Lead, GlobalDevelopment, Clinical Lead, Oncology Therapeutic Area,Roche Pharmaceuticals, USATomoko Hirohashi, Director, Japan Development Leader, Oncology,Pfizer Japan Inc., JapanSatoshi Koike, Director, Global Regulatory Affairs, Amgen-Astellas BiopharmaKK, Japan

REGISTER TODAY! +65 6508 2401 [email protected] www.oncologyasia.com

ASIA2ND ANNUAL

MONDAY 7 September 2015CONFERENCE DAY ONE

8:00 Registration Opens & Morning Coffee

8:45 Welcome Address from IBC AsiaSpeed Networking: Exchange Business Cards & Get to Know Industry Peers

8:50 Chairperson’s Opening Remarks:Pabel Delgado, President & CEO, Asterism Healthcare GK, Japan

ONCOLOGY MARKET OUTLOOK IN ASIA

9:00 Key Updates on Japan’s Healthcare & Health Insurance Policies• Overview of reimbursement policies for Japan• Compassionate use and its impact in the oncology space: international

and regional pharma company• Payer perspectives and key considerations when selecting and evaluating

oncology drugs to buy• What are the key considerations to get cancer therapeutics into the National

health insurance list?• Price revision rule updates in Asia• Health outcomes or health economics – critical support for formulary

approval or reimbursement effortsToshio Miyata, Executive Director, Health and Global Policy Institute, Japan

9:40 Considerations in Devising a Robust Oncology Market Access and PricingStrategy for Japan• Identifying barriers to treatment selection• Identifying the key markets for cancer types in Asia• Schemes and subsidies for better patient access to oncology drug• Factoring the tender-based nature of oncology drug products in Asian

marketsMichael Lyons, Innovation & Capability Leader, Oncology Business Unit,Eli Lilly KK, Japan

10:20 Morning Networking and Refreshment Break

11:00 Strategies for Developing and Commercialising Drugs for Asia TumourTypes• Oncology drug development trends through cancer epidemiology,

therapeutic areas and drug class – gastric cancer, liver cancer• Novel drug development based on indication, challenges in development

process in Asia• Novel small molecule inhibitors in oncology• New cancers on the rise in the Asian landscape• What are the therapeutic areas in oncology the pharma industry in Asia is

looking at and which areas are left undiagnosed?• Factors affecting drug access in Asia: how many diseases are going

undiagnosed?• Understanding and factoring the issue of drug cost for expensive oncology

treatments from patient’s perspectivesModerator:Jun Bao, Senior Vice President and Chief Business Officer, Shenogen PharmaGroup, ChinaPanelists:Bertil Lindmark, Chief Scientific Officer, ASLAN Pharmaceuticals, SingaporeXueming Qian, Chairman and Chief Executive Officer, Mabspace Biosciences,ChinaTing Xu, Chief Executive Officer, Alphamab, ChinaJin San Yoo, President, Chief Executive Officer, PharmAbcine, Korea

11:40 FDA Regulatory Updates on New Modality in Immuno-Oncology• New Modality in immuno-oncology• FDA’s regulatory perspectives• New drug development including breakthrough designation, fast tracking

approval and priority review• Case Study: Merck/Bristol-Myer’s Squibb immuno-oncology drug approvalMing Ji, Senior Medical Director, Medical Safety Evaluation, AbbVie GlobalResearch & Development, USA

LE

AD

ER

SH

IP P

AN

EL

DIS

CU

SS

ION

SPEC

IAL

REG

ULA

TOR

YU

PD

ATE

2:00 Onco-Immunotherapeutic Development in Alphamab: CheckpointInhibitor, Agonist and Bispecific Antibodies• Development of checkpoint inhibitory nanobodies though immunization

and focused library screening• Development of full human agonist antibodies with optimized yeast display

system• Development of multifucntion biologics for onco-immunotherapyTing Xu, Chief Executive Officer, Alphamab, China

BIO

TE

CH

CA

SE

ST

UD

Y

PA

NE

LD

ISC

US

SIO

N

2:40 Combinatory Approaches of Targeting Tumor Microenvironment forCancer Treatment• Highly differentiated immune checkpoint regulator antibody with better

tumor penetration• Increase tumor infiltrating T cells via normalization of dysregulated

angiogenesis and combination with PD-1/PD-L1 pathway inhibition• Increase immune response to tumor antigens by enhancing DC activation

and combination with PD-1/PD-L1 pathway inhibition• Targeting tumor stoma fibroblast and combination with immune checkpoint

inhibitorsXueming Qian, Chairman and Chief Executive Officer, Mabspace Biosciences,China

BIO

TE

CH

CA

SE

ST

UD

Y

Tackling Clinical and Real World Late Phase Study Challenges in Asia• Tackling challenges in target patient enrollment• Key considerations and solutions for post-clinical developmentMartina Sersch, Senior Medical Director, Asia Pacific Bio-therapeutics Lead, GlobalDevelopment Clinical Lead, Oncology TA, Roche Pharmaceuticals, USA

3:20 Afternoon Networking and Refreshment Break

5:20 Chairperson’s Closing Remarks5:30 End of Conference Day One

DRUG DISCOVERY AND PRECLINICAL DEVELOPMENT LATE PHASE DEVELOPMENT AND COMMERCIALIZATION

Developments in Cancer Therapeutic Space Optimizing Oncology Clinical Development Strategy for Asia

4:40 GC1118, A Novel Anti-EGFR Antibody with Distinct Binding Epitope andEfficacy• Key differences in EGFR antibodies in development in their forms in terms

of antibody mixtures, drug conjugates, action mechanism, and targetdisease areas

• Distinct binding epitope of GC1118• Spectrum of EGFR ligands and cancer cell types that are inhibited• Potential hypothesis in working mechanism and clinical implications of

GC1118Jonghwa Won, Senior Research Director, Mogam Biotechnology ResearchInstitute, Green Cross Corp., Korea

Delivering the Right Studies at the Right Time in the Right Way to Meet theReal-World Evidence Needs• Quality not quantity in observational research• Delivering oncology observational studies in Asia• Late Phase excellence in Oncology: insights from experts

PO

LIC

Y U

PD

AT

E

12:20 Networking Lunch & VIP TablesVIP Table 1: Takato Noumi, Director, External Science & Partnering, Sanofi Global R&D, JapanVIP Table 2: Naoki Okamura, Corporate Vice President, Head of Global Business Development, Astellas, JapanVIP Table 3: Simon Collier, Director General, European Federation of Pharmaceutical Industries and Associations,Director, Government Affairs, Bayer Yakuhin Ltd., Japan

Bring your questions, exchangebusiness cards and get to know key

industry experts during Lunch!

NE

WR

ES

EA

RC

H

4:00 Novel RNAi-Based Therapeutic Approaches for Cancer Stem Cells• Evidence for cancer stem cells (CSCs) having self-renewing ability and

tumorigenesis• Examining paradigm shift for breast cancer biology and treatment strategies

through CSC• Current development of a novel therapeutic approaches against CSCs by

RNAi-based medicineTakahiro Ochiya, Chief, Division of Molecular and Cellular Medicine,National Cancer Center Research Institute, Japan

Optimizing and Evaluating the Oncology Clinical Development Pathwayin Japan Through Kampo Igaku• Kampo Medicine in Japan and applications in Oncology Clinical Trials• Investigator-initiated trials in Japan and Kampo Therapy• Evaluating Kampo Igaku in Chemotherapy and patient Quality Of LifeKenji Watanabe, Clinical Oncologist, Director, Professor, Faculty of Environmentand Information Study, Keio University School of Medicine, Japan

CLI

NIC

AL

ON

CO

LOG

IST

PER

SPEC

TIV

E


ASIA2ND ANNUAL

TUESDAY 8 September 2015CONFERENCE DAY TWO

8:00 Registration Opens & Morning Coffee

8:50 Chairperson’s Opening RemarksPabel Delgado, President & CEO, Asterism Healthcare GK, Japan

R&D PARTNERSHIPS AND COLLABORATION STRATEGIES

9:00 Innovative Partnerships and Collaborative R&D Models for Oncology Drug Discovery and Development in Asia• How to attract big pharma partnerships?• Exploring different collaborative models for oncology drug development• Partnering and investment strategies for big pharma in Asia: What do big pharma look out for?Dr. M. C. Fung, Vice-President, Oncology Scientific Innovation, Johnson & Johnson Asia-Pacific Innovation Center, China

9:40 Bridging Academic Science and Clinical Research in the Search for Novel Targeted Anti-Cancer Agents• Case studies demonstrating academic research translation into clinical development• Asian landscape overview of innovation in academic research in the oncology space• How to bring academic research to commercialization?Alex Matter, Former Global Head of Research, Novartis Oncology, Chief Executive Officer, Experimental Therapeutics Centre, A*Star, Singapore

11:40 Role of Biomarkers for Cancer Drug Development

• Biomarkers: supporting discovery all the way to clinical development• Cancer genomics and genetic data in Biomarker development• Exploring protein biomarker in development• Imaging (MRI/PET)Yoshiya Oda, President, Biomarkers & Personalized Medicine Unit, Eisai Inc, USA

Leveraging Insights from Real World Data to Create Compelling MarketingStrategies• Opportunities and issues: Real world data gathering and usage from Pharma

company perspective• How to use post marketing data in creating effective marketing and

promotion strategies?• Effectively providing scientific and clinical input into key commercial

initiatives• Effectively conveying the results in medical publications• Real World Data and new evidence-based modelling for improving patient

outcomes• Impact of oncology outcomes research on the brand• Leveraging Real World Evidence to manage budgets, positioning for

pathway and guidelines• Linking and interrogating disparate datasets while adhering to privacy

and other requirementsPanelists:Martina Sersch, Senior Medical Director, Asia Pacific Bio-therapeutics Lead,Global Development Clinical Lead, Oncology TA, Roche Pharmaceuticals, USAMing Ji, Senior Medical Director, Medical Safety Evaluation, AbbVie GlobalResearch & Development, USA

PA

NE

LD

ISC

US

SIO

N

12.20 Precision Lung Cancer Medicine Based on Oncogene Fusion and

Chromatin Regulation Deficiency

• RET fusion is a druggable oncogene for lung cancer therapy using existingkinase inhibitors

• Deleterious mutation in SMARCA4, a chromatin remodeling gene, is atarget for synthetic lethal therapy

• Clinical sequencing to detect multiple gene mutations in cancer cells areon-going in National Cancer Center, Japan

Takashi Kohno, Chief, Division of Genome Biology Research Institute,National Cancer Center Research Institute, Japan

Designing a Sustainable Health Economics & Outcomes Research Strategyfor Asia• Designing health outcomes research strategy for North Asia• Generating and communicating evidence for access and reimbursement

decisions to key stakeholders• Key consideration in designing outcome research and pharmacoeconomic

evaluation• Managing Health Technology Assessment (HTA) requirements• Using HEOR, epidemiology for meaningful data analytics and accessing

the volume and profitability of the marketJean-François Baladi, Senior Executive, Health Economics and Market Access,Oncology Business Unit, Novartis Pharma K.K., Japan

1:00 Networking Lunch

2:00 Clinical Development of a Defucosylated Anti-CCR4 Humanized Antibody,Mogamulizumab in ATL, PTCL and CTCL• Mogamulizumab: first-in-class anti-chemokine receptor 4 (CCR4) humanized

antibody approved for treatment of patients with ATL, PTCL and CTCL inJapan

• Higher ADCC activity due to defucosylation• Dual mechanism of action: A direct killing of CCR4 positive tumor cells and

a depletion of CCR4 positive effector regulatory T cells to enhance cancerimmunity

Shiro Akinaga, Fellow, Research and Development Division, Kyowa HakkoKirin Co. Ltd., Japan

Pricing Considerations for Global Rollout of Cancer Drugs• Launch price considerations for oncology drugs• Pricing strategy: Which country and what price?• Launch price considerations for oncology drugs in Asia• Case study: Pricing for success in the Asian reimbursed economies

2:40 Progress of Tanibirumab Phase II and Its Next Generation BispecificAntibody on Challenging Cancer• Pathway from discovery to development of tanibirumab, a fully human

monoclonal antibody, in Korea• Its applications in the cancer therapeutic areaJin San Yoo, President, Chief Executive Officer, PharmAbcine, Korea

4:00 Antibody Drug Conjugate Using Celltrion’s Own Linker and Drug• Characterization of Novel Linkers-Payloads on ADCs• Molecular properties of novel linkers and payloads that potentially

compromise ADC critical quality attributes• Analytical and biophysical characterization techniques to de-risk novel

linkers and payloads• Potential analytical techniques to identify degradation and destabilization

pathways• Celltrion’s ADC linker and drug case studyShin Jae Chang, Vice President, R&D, Celltrion, Korea

10:20 Morning Networking and Refreshment Break

3:20 Afternoon Networking and Refreshment Break


Genomics In Cancer Drug Development Real World Evidence, Health Economics And Outcomes Research

ST

RA

TE

GY

TAL

K

Fully Human Monoclonal Antibodies and Antibody Drug Conjugate Pricing For Success

The Pharmaceutical Pricing Policy Environment in Japan• The progress Japan has made in reducing the drug lag• Creating a pro-innovation environment for pharmaceuticals.• Ideas for reform of the Japanese pricing system and introduction of health

technology assessment (HTA)Simon Collier, Director General, European Federation of Pharmaceutical Industriesand Associations Japan, Head of Governmental Affairs, Bayer Yakuhin Ltd., Japan

NE

WR

ES

EA

RC

H

Understanding the Value Of Oncology Assets: Evaluating MarketDynamics and Pricing• Evaluating an oncology drug for Japan, KOL interactions, pricing, prescribers'

practices, doctors’ concerns regarding safety and efficacy• What are the patient’s needs? What are the pharma company’s concerns?• How to demonstrate the value of the oncology product to payers?Gaël Le Rouzo, Business Director, Jazz Pharmaceuticals, FranceKenji Watanabe, Clinical Oncologist, Director, Professor, Faculty of Environmentand Information Study, Keio University School of Medicine, Japan

PA

NE

LD

ISC

US

SIO

N

11.00 Revolutionizing Cancer Genomics and Drug Discovery in Asia Through

Next Generation Sequencing

• Moving “omics” to the clinic• Understanding the clinical utility for genomic testing• Clinical NGS: cancer, disease research & tumour testing• Using NGS for precision & personalised medicine• Supporting clinical decision-making through genomic sequencingTed van der Lende, Senior Director, Companion Diagnostic Partnerships, GlobalBusiness Development, Qiagen, UK


ASIA2ND ANNUAL

TUESDAY 8 September 2015CONFERENCE DAY TWO

4.40 Developing a Robust Predictive Model for Liver Cancer• Identifying solutions for targeting liver cancer based on knowledge of liver

oncogenic pathways• Leveraging liver cancer patient samples for translational approaches• Exploring immunotherapies for controlling liver cancerLiang Schweizer, Head of Asian Cancer Research, Asia Pacific Research,Sanofi R&D, China

Tips and Lessons in Launch Readiness for Oncology Products• How to maximize the potential of a new product? Tackling the pricing and

reimbursement factors in the oncology space• Launching in as many countries as possible, as fast as possible and evaluating

key considerations for launch readiness• Exploring simultaneous launch for oncology products• ICH-E5 introduction, global launch under a pivotal study, HTA of NICE/UK

scheme and MHLW introduction of HTA from 2016• Key consideration for the launch preparation of new products and

establishing an effective marketing strategy for cancer drug launchKoichi Okuma, Executive Director, Strategic Marketing, Head of OncologyTherapeutic Area, Product Marketing Department, Astellas Pharma, Japan

Approaches for Asian Companies to Access the Global Oncology Market• Devising a successful global launch strategy• Assessing the competition for the product in intended launch market• What are the costs involved to go global and to get the drug registered in

the market?• Is out-licensing an efficient way for Asian companies to accelerate market

penetration in new markets outside and inside Asia?• Case Study: Breaking into the US/EU markets: key drivers for success and

key considerations for market access

5:40 Chairperson’s Closing Remarks | End of Conference Day Two

POST-CONFERENCE WORKSHOPS 9 SEPTEMBER 2015

Workshop A: 9:00 am - 12:30 pm Workshop B: 1:30 pm - 4:30 pm

With more pharmaceutical companies focusing on oncology drugdevelopment and increasing scrutiny of national payors for oncology products,it is becoming increasingly important to think of innovative and creativestrategies for enhancing patient adherence to Oncology Drugs and evaluatingnew methods to market the product via social media. Practical case studiesand key considerations will be noted along with discussion of the challengesfaced and how to tackle these challenges.

By attending this half-day workshop, participants willshare experience and gain:

• Insights into utilizing social media to effectively engage patients• Strategies to help patients identify and understand more about the disease

and cure• Knowledge on what has worked and what has not in the field of oncology

marketing and innovation

Creative Strategies for Better PatientAdherence to Oncology Drugs in Asia

Gaining FDA Regulatory Approvals forAccelerated Drug Development and PriorityReview in Immuno-Oncology

This interactive workshop is aimed at all professionals with interest in exploringthe pathways for accelerated drug development and approval throughunderstanding global and Asian regional regulatory requirements. This sessionwill explore the key considerations and areas to look at for different countriesin Asia as well as USA for launching the oncology drug to market in the fastestway.

By attending this half-day workshop, participants will shareexperience and gain:

• A greater understanding of FDA regulatory approval requirements innew drug development which include breakthrough designation, fasttrack, accelerated approval and priority review

• A comparison of global submissions and Asia submission – strategies inbenefit and risk assessment, new drug safety profiling, regulatoryinteractions and submissions

About Your Workshop Leader

Ming JiSenior Medical Director, Medical SafetyEvaluation,AbbVie Global Research &Development, USA

Michael LyonsInnovation & Capability Leader,Oncology Business Unit,Eli Lilly KK, Japan

About Your Workshop Leader

Michael K. Lyons is a pharmaceutical professional with 14 years ofexperience (10 years Oncology) in Japan, USA, Europe and SoutheastAsia. As the first expatriate for Lilly Oncology Japan, he serves as theInnovation Leader, directing the teams of New Product Planning(early phase, development portfolio), Brand, and Public Policy.

At Lilly, where has received the company's highest honors and awards,Michael led Japan’s launch of CYRAMZA®; reversed Japan’s branderosion of GEMZAR®; created 1st social media footprint in Japanpharmaceutical industry; led Thai affiliate +9% oncology, +4% portfoliogrowth; and launched, managed ALIMTA® in US & Europe.

Novel Cancer Biomarkers Product Launch And Marketing Strategies For Cancer Drugs


ST

RA

TE

GY

TAL

K

NE

WR

ES

EA

RC

HN

EW

RE

SE

AR

CH

Dr. Ming Ji is senior medical director at Global R&D of Abbvie, which provides productsafety evaluation and safety profile development, benefit/risk assessment,communication and management for post marketing products and products in clinicaldevelopment. Prior to joining Abbott/Abbvie in 2009, Dr. Ji served in a number ofpositions at other pharmaceutical companies including medical monitor in ClinicalDevelopment of Wyeth; medical director at R&D of TAP Pharmaceutical Inc. andexecutive director at Global Safety of Amgen Inc. Dr. Ji developed his core career inthe areas of clinical drug safety and new drug development. He also developed interestand expertise in risk management and risk-benefit assessment. Ming has led variousgroups in clinical development, drug safety, early- phase development and life cyclemanagement of pharmaceutical and biological products. Dr. Ji has developed globalsafety and risk management programs across multiple therapeutic classes.

Dr. Ji received his Medical Degree from Shandong Medical School and MS in clinicalresearch at Tianjin medical school in China. He practiced medicine at Tianjin hospital,Tianjin, China for 10 years before joining Radiation Oncology Research Institute atEvanston Hospital of Northwestern University. His academic career in oncology researchwas focused on the discovery and development of new molecular entities forsensitization of chemotherapy and radiation therapy, led to a number of publicationsin peer reviewed journals.

5.00 Early Detection for Tumor Markers through Acoustic Biosensor• Clinically predictive biomarkers and patient identification through early

detection• Unique specimen sampling methods to achieve the effect of cancer in early

detection• Case Study: Successful results for nasopharyngeal carcinoma and ovarian

cancer detectionGeorge Chen, Director, Biomedical Sensing & Oncology Lab, Professor, Instituteof Biomedical Engineering, Department of Biological Science and Technology,National Chiao Tung University, Taiwan

By Industry■ Government 5%■ Pharma & Biotech 50%■ CROs 15%■ Technology & Solution Providers

20%■ Research Institutes / Healthcare

Agencies & Industry Association10%

By Geography■ Japan 50%■ China/Taiwan/Hong Kong 15%■ South Korea 20%■ Europe/USA/Australia/Canada 10%■ Singapore and RoW 5%


IBCLIFE SCIENCES

ASIA2ND ANNUAL

7 - 9 September 2015 | Sheraton Miyako, Tokyo, Japan

What’s New in 2015?The only event in Asia focusing on cutting-edge immuno-oncologydrug discovery and preclinical research and cutting-edge newadvances in immuno-oncology!TWO separate parallel tracks focusing on drug discovery and latephase-commercialization!More case studies involving small innovative biotech and largepharma commercialization and drug discovery in Asia!Strategically located at Asia’s leading R&D destination – Japan!Multitude of interactive sessions for you to discuss on the variousreal solutions in the drug discovery and market access space foroncology

Hear Some of the RaveReviews from Attendees atIBC Life Sciences’ Events!

“Thanks for a great conference!”Boehringer Ingelheim Pharmaceuticals, USA

“IBC has created a pioneering summit in Tokyoto open the doors of the highly innovativeJapanese pharma industry for overseasinteractions”Orchid Research Laboratories, India

“I walked away with indepth understanding oftrends in bioproducts/biosimilars, regulatoryhurdles, market access”Besins, China

“Excellent conference”Merck Serono, Switzerland

“Provided great exposure to local R&Dorganisations”PerkinElmer, USA

SPONSORSHIP OPPORTUNITIESRaise awareness for your services available to Drug Discovery andDevelopment Value Chain in Asia1. Would you like to raise your visibility in the Drug Discovery and

Development industry?2. Could you benefit from showcasing your products & services

before key industry players?3. Are you seeking the lowest cost way of meeting a target audience

of decision-makers from the following industries?• Drug discovery• Pre-clinical development• Clinical Development• Late phase Development and Medical Affairs• Commercialization or Market access

If so, we can help you achieve your goals, perhaps what you needis a branding opportunity at this event! Increase your reach throughour extensive marketing campaign, targeted at your qualifiedbusiness audience.

For information about placing your brand & profile top-of-mind tokey buyers, contact Yvonne Leong, Business Development Manageron Tel: +65 6508 2489 or Email: [email protected]

Who Should Attend

The second installment of IBC’s Oncology Asia zeroes in on thelatest cutting edge developments in oncology drug discoveryand late phase strategies to get oncology drugs to market faster!Under the Drug Discovery track, this conference will discusslatest immune checkpoint inhibitor combinations, preclinicaldevelopment trends, novel biomarkers and oncology drugdevelopment case studies in Asia. Under the late phase track,it will discuss pricing for success, global and regionalcommercialization case studies, healthcare policy updates andpricing for success.

On 7-9 September, find out about the latest drug discoverytrends along with latest strategies for global and regionalcommercialization at the ONLY senior industry gathering

focused on advancing cutting edge oncology R&D andcommercialization strategies for Asia in Tokyo, Japan!


This label contains your priority booking code. To expedite registration, please do not remove label. If you havealready received a copy of this brochure, we apologise. For reasons of confidentiality, your full particulars were notavailable to IBC Asia (S) Pte Ltd for deduplication prior to mail drop.

If undelivered, please return to:

111 Somerset Road,TripleOne Somerset #10-05, Singapore 238164Tel: +65 6508 2400 Fax: +65 6508 2408

2nd Annual Oncology Asia

ENJOY SUBSTANTIAL SAVINGS WITHOUR MULTIPLE BOOKING DISCOUNT!

[email protected]

Fax+65 6508 2407

Scan the QR Code with yoursmartphone and register today

Customer Service Hotline+65 6508 2401

MAIL the attached registrationform with your cheque toIBC Asia (S) Pte Ltdc/o Informa Regional BusinessServices111 Somerset Road,TripleOne Somerset #10-05,Singapore 238164

Webwww.oncologyasia.com

HOTEL INFORMATION

DATA PROTECTION

PAYMENT TERMS

CANCELLATIONS / SUBSTITUTION

IMPORTANT NOTE

REG

NO. 2

0010

8203

N

Payment must be received 10 business days prior to the event.To take advantage of discounts with an expiry date, registrationand payment must be received by the cut-off date.• Payment by bankers draft or cheque in S$ or US$ should

be made in favour of “IBC Asia (S) Pte Ltd” and mailed to:IBC Asia (S) Pte Ltdc/o Informa Regional Business Services111 Somerset Road, TripleOne Somerset #10-06Singapore 238164Attn: The Accounts Receivable Team

• Payment by bank transfer in S$ or US$ made payable to:IBC Asia (S) Pte LtdA/C No.:147-059513-001 (S$)A/C No.:260-457866-178 (US$)The Hongkong and Shanghai Banking Corporation Limited21 Collyer Quay, HSBC BuildingSingapore 049320Bank Swift Code: HSBCSGSGBank Code: 7232

• Payment by Credit Card (AMEX, VISA or MasterCard).The best way to pay by credit card is through our secureportal built into the website. To pay by phone please indicatethe contact name and details below and our CustomerServices Team will call within 24 hours to take payment.Please do not send credit card information by email.

The personal information entered during your registration/order,or provided by you, will be held on a database and may beshared with companies in the Informa Group in the UK andinternationally. Occasionally, your details may be obtained fromor shared with external companies who wish to communicatewith you offers related to your business activities. If you do notwish your details to be used for this purpose, please contactour Database Department at Email: [email protected],Tel: +65 6508 2400 or Fax: +65 6508 2408.

Should you be unable to attend, a substitute delegate iswelcome at no extra charge. Cancellations must be received inwriting at least 10 business days before the start of the event,to receive a refund less 10% processing fee per registration.The company regrets that no refund will be made available forcancellation notifications received less than 10 business daysbefore the event.

Please quote the name of the delegate, event title and invoicenumber on the advice when remitting payment. Bank chargesare to be deducted from participating organisations own accounts.Please fax your payment details (copy of remittance advice,cheque or draft to +65 6508 2407).Attendance will only be permitted upon receipt of full payment.Participants wishing to register at the door are responsible toensure all details are as published. IBC assumes no furtherliability or obligation, beyond the refund of the paid registrationfee, in the event of postponement or cancellation by IBC.

6 EASY WAYS TO REGISTER

RESERVE YOUR PLACE TODAY!■ Yes! I/We will attend the 2nd Annual Oncology Asia • 7 – 9 September 2015, Sheraton Miyako, Tokyo, Japan■ I would like to purchase the conference presentations at SGD1000 + GST (SGD1070) per log in.

CREDIT CARD PAYMENTSThe best way to pay by credit card is through our secure on-line registration process, simply log on to the website atwww.oncologyasia.com and click “Register On-line”. If you would prefer to pay over the phone please complete the contact nameand details and our Customer Services Team will call within 24 hours to take payment. As we treat your credit card information in thestrictest confidence, please do not send payment details by email.

Credit card contact: Department:

Direct phone number: Email:P46282

Who is Head of your Department?Who is Head of Training?

Company InformationCompany Name:

Address:

Main Business/Activity:

Postal Code:

■ I enclose my bankers draft / cheque payable to IBC Asia (S) Pte Ltd■ I am paying by bank transfer (copy attached)■ Payment by Credit Card. (AMEX, VISA or MasterCard accepted)

PAYMENT METHOD(Please tick)

• Multiple Bookings Discount pricing is applicable to groups of 3 or more delegates from the same organisation registering for the same event, at the same time.Fee stated is the discounted price PER DELEGATE. Only one discount applies; either the early bird rate OR special rate OR group rate.

• All fees stated include luncheons, refreshments and complete set of documentation. It does not include the cost of accommodation and travel.• Registration fees are subject to the prevailing government tax

Please photocopy for additional delegates

Delegate 1 Details Delegate 2 DetailsName: Dr/Mr/MsJob Title:DepartmentTel:Mobile No.:Email:

Delegate 3 Details Delegate 4 Details

Early Bird RateRegister & pay on orbefore 10 Jul 2015

Special RateRegister & pay on orbefore 7 Aug 2015

Group Rate(3 or more delegates)

Normal RateRegister & pay after

7 Aug 2015

❑ 3 Day Package: 2 Day Conference +Post-Conference Workshop A & B

FEE PER DELEGATE

USD 2,295 USD 2,495 USD 2,695 USD 2,195

GROUP BONUS – Register 3 Delegates from the same company and the 4th Delegate attends FREE!

Name: Dr/Mr/MsJob Title:DepartmentTel:Mobile No.:Email:



❑ 2 Day Conference only

❑ 2.5 Day Package: 2 Day Conference +❑ Post-Conference Workshop A❑ Post-Conference Workshop B

USD 2,095 USD 2,295 USD 2,495 USD 1,995

USD 1,895 USD 2,095 USD 2,295 USD 1,795

❑ 3 Day Package: 2 Day Conference +Post-Conference Workshop A & B USD 1,995 USD 2,195 USD 2,395 USD 1,895

❑ 2 Day Conference only

❑ 2.5 Day Package: 2 Day Conference +❑ Post-Conference Workshop A❑ Post-Conference Workshop B

USD 1,795 USD 1,995 USD 2,195 USD 1,695

USD 1,595 USD 1,795 USD 1,995 USD 1,495

PHARMACEUTICAL COMPANY RATES

INDUSTRY RATES

Sheraton Miyako Hotel1-1-50 Shirokanedai, Minato-ku,Tokyo 108-8640Phone: +011-81-3-3447-3111Fax: +011-81-3-3447-3133

2nd Annual Oncology Asia Brochure

Documents

Transcript of 2nd Annual Oncology Asia Brochure